Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177lu-DOTATATE and 90Y-DOTATOC

Purpose: Peptide-receptor radionuclide therapy (PRRT) with somatostatin analogs is an efficient new tool in patients with neuroendocrine tumors, with low risk of toxicity. Since lymphocytes express somatostatin receptors, the aim of this study was to evaluate lymphocytic toxicity after PRRT. Methods: From May 2005 to May 2007, 16 patients affected by neuroendocrine tumors received PRRT with 90Y-DOTATOC (9), 177Lu-DOTATATE (5), or both (2). Absolute count, percentage of leukocytes and lymphocytes, and lymphoid subsets (B, T, and NK) were tested at baseline and until 90 days after treatment. Results: A significant lymphoid toxicity (G2-3), mainly affecting B-cells, was observed. It was particularly evident after 90Y-DOTATOC. Toxicity resulted in being transient and resolved completely at the end of the follow-up (90 days). Conclusion: Lymphocyte toxicity in PRRT is mainly due to the selective targeting on B-cells. The relative sparing of T-lymphocytes could explain the absence of clinical side-effects in these patients, such as increased risk of infections. These findings open interesting perspectives in the treatment of B-cell lymphoproliferative disorders. © 2009 Mary Ann Liebert, Inc.

Data di pubblicazione: 2009
Titolo: Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177lu-DOTATATE and 90Y-DOTATOC
Autori: Sierra, Maribel L.; Agazzi, Alberto; Bodei, Lisa; Pacifici, Monica; Arico, Demetrio; De Cicco, Concetta; Quarna, Jessica; Sansovini, Maddalena; De Simone, Michele; Paganelli, Giovanni
Rivista: CANCER BIOTHERAPY & RADIOPHARMACEUTICALS
Parole Chiave: Radionuclide therapy; Radiopharmaceuticals; Targeted therapy; Cancer Research; Oncology; Radiology, Nuclear Medicine and Imaging; Pharmacology
Abstract in inglese: Purpose: Peptide-receptor radionuclide therapy (PRRT) with somatostatin analogs is an efficient new tool in patients with neuroendocrine tumors, with low risk of toxicity. Since lymphocytes express somatostatin receptors, the aim of this study was to evaluate lymphocytic toxicity after PRRT. Methods: From May 2005 to May 2007, 16 patients affected by neuroendocrine tumors received PRRT with 90Y-DOTATOC (9), 177Lu-DOTATATE (5), or both (2). Absolute count, percentage of leukocytes and lymphocytes, and lymphoid subsets (B, T, and NK) were tested at baseline and until 90 days after treatment. Results: A significant lymphoid toxicity (G2-3), mainly affecting B-cells, was observed. It was particularly evident after 90Y-DOTATOC. Toxicity resulted in being transient and resolved completely at the end of the follow-up (90 days). Conclusion: Lymphocyte toxicity in PRRT is mainly due to the selective targeting on B-cells. The relative sparing of T-lymphocytes could explain the absence of clinical side-effects in these patients, such as increased risk of infections. These findings open interesting perspectives in the treatment of B-cell lymphoproliferative disorders. © 2009 Mary Ann Liebert, Inc.
Digital Object Identifier (DOI): 10.1089/cbr.2009.0641
Handle: http://hdl.handle.net/11392/2383033
Appare nelle tipologie:03.1 Articolo su rivista

File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
 
 
 
Powered by IRIS-about IRIS-Utilizzo dei cookie
Logo CINECA  Copyright © 2022